Bankruptcies
Filter News
Found 391 articles
-
Akorn Successfully Completes Sale to Lenders and Exits Chapter 11 Protection
10/2/2020
Company positioned to enter its next phase of growth with new ownership and a more sustainable capital structure
-
Akorn Receives Court Approval of Sale to Lenders
9/2/2020
Akorn, Inc., a leading specialty pharmaceutical company, announced that the United States Bankruptcy Court for the District of Delaware has approved its sale to the Company's existing lenders.
-
VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC
7/7/2020
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing.
-
Two years after Germany’s Fresenius Medical Care walked away from a 2017 $4.3 billion deal to acquire Akorn Pharmaceuticals, the company has filed for protection under U.S. bankruptcy laws as it attempts to restructure for a potential sale.
-
Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success
5/21/2020
Continues Operations as Usual, Delivering Safe and Effective Products to Customers and Patients
-
Sophiris Bio To Shut Down Operations
5/18/2020
Sophiris Bio Inc., announced that its board of directors has formally approved an immediate shutdown of the operations of the Company.
-
Rising Pharma Holdings Inc.’s Statement Regarding Recent Articles
3/23/2020
Several recent articles inaccurately state an affiliation between Rising Pharma Holdings, Inc., and Rising Pharmaceuticals, Inc., and its parent company, ACETO Corporation.
-
Deerfield Management placed Melinta’s assets up for auction, but no other companies made competing bids, leaving Deerfield in control of the company’s assets.
-
Mallinckrodt Files Chapter 11 for its Generics Business as it Reaches $1.6 Billion Opioid Settlement
2/25/2020
In addition to the settlement and bankruptcy, Mallinckrodt entered into a debt refinancing agreement, including an $800 million loan that will be used to repay some outstanding debt and acquire some outstanding stocks. -
Purdue Taps Tom Vilsack, Former Cabinet Secretary and Governor, to Monitor Compliance With Voluntary Injunction
2/21/2020
Feb. 21, 2020 15:13 UTC STAMFORD, Conn.--( BUSINESS WIRE )-- Purdue Pharma L.P. (“Purdue”) today announced the appointment of former United States Agriculture Secretary and Iowa Governor Tom Vilsack as Monitor under the voluntary self-injunction approved on November 6, 2019, in its chapter 11 bankruptcy case. In its initial bankruptcy filings, Purdue voluntarily proposed to formalize under court order its commitment to continue to refrain from engaging in certain promotional
-
Aradigm Announces Entering into an Asset Purchase Agreement with Grifols, S.A.
2/21/2020
Feb. 21, 2020 13:00 UTC NEWARK, Calif.--( BUSINESS WIRE )-- Aradigm Corporation (OTC PINK: ARDM) (“Aradigm” or the “Company”) today announced that the Company has entered into an Asset Purchase Agreement pursuant to which Grifols, S.A. (the “Buyer”) will acquire the Company’s assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof. The sale is subject to the approval of the Bankruptcy Court, and is subject to the results o
-
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures
2/13/2020
Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers
-
Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business
2/12/2020
Akorn, Inc., a leading specialty pharmaceutical company, announced it has reached an agreement with certain of its lenders to extend the standstill period.
-
Valeritas Announces Agreement for Zealand Pharma to Acquire Business and Retain Employees
2/10/2020
Valeritas Holdings, Inc., a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced an agreement to sell substantially all of the business to Zealand Pharma A/S, a Denmark-based biotechnology company.
-
Novelion Therapeutics Confirms Commencement of Voluntary Liquidation
1/17/2020
Novelion Therapeutics Inc. announced that the implementation of the Company’s voluntary liquidation commenced at 5:00 p.m. Pacific Time, January 16, 2020.
-
Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea
1/13/2020
New chemical entity and selective muscarinic receptor antagonist targeting large unmet need for a new treatment that can meaningfully improve the lives of patients with neurological conditions
-
Novelion Therapeutics Announces January 16, 2020 Effective Date for Commencement of Voluntary Liquidation
1/10/2020
Novelion Therapeutics Inc. announced the definitive date for commencement of implementation of the Company’s voluntary liquidation as 5:00 p.m. Pacific Time on January 16, 2020.
-
The decision to file Chapter 11 followed a close examination of the company’s strategic options and current financing.
-
NPXe Files Voluntary Chapter 11 to Implement 363 Asset Sale
12/30/2019
NPXe Limited announced that it has filed a voluntary petition to reorganize under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
-
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
12/27/2019
Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations